Spectral Med Inc is seeing a positive uptick in its stock price, gaining 2.21% in the last trading session, closing at CA$1.39.
In a notable move on the TSX, Spectral Med Inc (EDT.TO) has experienced a 2.21% increase in its stock price during the last trading session. This rise comes amid ongoing developments in the company's clinical trials and financial strategies, which are capturing the attention of investors.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$390.25M
52W high
$1.76
52W low
$0.77
1W change
+2.26%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 131.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+131.6% Upside
Current Price
C$1.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
22.4%
Annualized
90-Day Vol
33.7%
Annualized
Trend (90d)
-9.2%
Annualized drift
90d Mean
C$1.32
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.35 | C$1.25 โ C$1.45 |
| 60 trading days | C$1.33 | C$1.19 โ C$1.48 |
| 90 trading days | C$1.32 | C$1.15 โ C$1.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on Spectral Med's advancements in clinical trials and its financial maneuvers, as these could significantly impact its market performance in the near future.
Spectral Med Inc Market Cap
With a market cap of CA$399 million, Spectral Med Inc is positioned as a significant player in the biotech sector, but it still faces challenges in demonstrating consistent revenue generation.
Bull case
The recent publication of the Tigris trial results in The Lancet Respiratory Medicine has reaffirmed the effectiveness of Spectral's PMX-20R treatment. This could boost investor confidence and spark more interest in the market.
Bear case
Despite the positive movement, investors should remain cautious. The company has yet to achieve profitability, and how the market reacts to future trial results could be unpredictable.
Positive Trial Results Boost Investor Confidence
The recent publication of the Tigris trial results has confirmed positive outcomes for Spectral's PMX-20R treatment, which could significantly reduce 28-day mortality rates. This news has likely contributed to the stock's upward movement as investors react to the potential for future market success.
Financial Strategies and Market Position
Spectral Med's recent non-dilutive financing arrangements with Vantive, which include up to US$10 million, provide a strong financial backbone as the company prepares for commercialization. This financial strategy may enhance investor confidence, reinforcing the stock's positive trajectory.
Advertisement
